CORONA REMEDIES LIMITED

The investor presentation from CORONA Remedies Limited, dated July 31, 2026, provided an overview of the company's performance for the quarter ended June 30, 2026. The presentation highlighted a revenue of INR 422.4 crore, reflecting a year-on-year growth of 21.9%. EBITDA was reported at INR 93.1 crore with a margin of 22.0%, and profit after tax (PAT) was INR 60.1 crore, marking a 30.1% increase. Management noted that the company ranked 26th in the Indian Pharmaceutical Market (IPM) as of June 2026, up from 27th in March 2026. The presentation also emphasized the inauguration of a new EU-GMP certified hormone manufacturing facility and the company's strategic focus on chronic therapies, which contributed approximately 73.4% of revenue in Q1 FY27. Additionally, management outlined future growth strategies, including expanding into new therapeutic areas and enhancing market share.

Management emphasized strong financial performance and growth initiatives.